Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS) to extend its PharmacyChain blockchain-related technology beyond pharmaceutical distribution into commercial healthcare, healthspan and wellness applications. The expanded relationship is designed to support patient-controlled health data access, monetization and real-world asset tokenization across pharmacy, medical, laboratory and wearable device environments, leveraging a behavioral healthcare patent portfolio focused on medical logistics, IoT population health and AI-driven remote patient monitoring.
Under the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This move is significant because it marks a strategic expansion of Datavault AI's technology into the healthcare sector, a market with substantial growth potential. The global health and wellness market is expanding rapidly, and the ability to tokenize real-world assets and enable patient-controlled data access could transform how healthcare data is managed and monetized. By leveraging its behavioral healthcare patent portfolio, Datavault AI is positioning itself to address key challenges in medical logistics, IoT population health, and AI-driven remote patient monitoring.
For DataMeds AI, the agreement provides access to Datavault AI's blockchain technology, which can enhance data security and interoperability in healthcare. The issuance of common shares to Datavault AI aligns incentives between the two companies, fostering collaboration on new data transaction models. This partnership could serve as a model for other healthcare firms looking to integrate blockchain and AI solutions.
Investors should note that Datavault AI's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
For more details, the full press release is available at https://ibn.fm/vBAxH. Additional information about Datavault AI can be found at https://dvlt.ai.
